Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Tesla Plans FSD Subscription Price Hikes as Autonomous Capabilities Advance 
JPMorgan and Allen & Company Emerge as Big Winners in Warner Bros Discovery Bidding War 
ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
Apple Stock Jumps as Company Prepares Major Siri AI Chatbot Upgrade 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Baidu Shares Surge After Official Launch of Advanced Ernie 5.0 AI Model 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
NEWARK, Calif., May 04, 2017 -- CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for specialty and orphan diseases with high unmet medical need, today announced that it will host a conference call and live audio webcast on Thursday, May 11th at 4:30 p.m. Eastern Time to discuss financial results for the first quarter ended March 31, 2017 and provide a business update.
Conference Call Details
To access the live conference call, please dial 877-407-0784 from the U.S. and Canada, or 201-689-8560 internationally, Conference ID# 13661044. To access the live and subsequently archived webcast of the conference call, go to the Investors section of the company's website at http://ir.cymabay.com/events.
About CymaBay
CymaBay Therapeutics, Inc. (CBAY) is a clinical-stage biopharmaceutical company focused on developing therapies for specialty and orphan diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist. A Phase 2 study of seladelpar in patients with mixed dyslipidemia established that it has an anti-atherogenic lipid profile. CymaBay has completed Phase 2 studies for seladelpar in subjects with primary biliary cholangitis and homozygous familial hypercholesterolemia, establishing proof-of-concept in both indications. Arhalofenate is a potential Urate-Lowering Anti-Flare Therapy that has completed five Phase 2 studies in subjects with gout. Arhalofenate has been found to reduce painful flares in joints while at the same time lowering serum uric acid by promoting excretion of uric acid by the kidney. This dual action addresses both the signs and symptoms of gout while managing the underlying pathophysiology of hyperuricemia. Arhalofenate has been licensed in the U.S. to Kowa Pharmaceuticals America, Inc. CymaBay retains full development and commercialization rights for arhalofenate outside the U.S.
For additional Information about CymaBay visit www.cymabay.com.
Contact: Sujal Shah CymaBay Therapeutics, Inc. (510) 293-8800 [email protected] Hans Vitzthum LifeSci Advisors, LLC 212-915-2568 [email protected]
